Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 5,201 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Neoplasm Clear all
Recruiting No phase listed Observational

DESTINY-PANTUMOUR04

NCT07124000
View directory record Official record
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated No phase listed Observational

Multiple Biomarkers in Undiagnosed Pleural Effusion

NCT00316134
View directory record Official record
Conditions
Pleural Effusion, Pleural Effusion, Malignant
Interventions
Procedure/Surgery
Procedure
Lead sponsor
Fujirebio Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional Results available

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

NCT06039384
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
INCB099280, adagrasib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Greeley, Colorado • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

NCT03689855
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
Interventions
Ramucirumab, Atezolizumab, Peripheral blood draw, Biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 28, 2026, 4:36 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

NCT04407247
View directory record Official record
Conditions
Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma
Interventions
Infliximab, Vedolizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

NCT03637816
View directory record Official record
Conditions
Anorexia, Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Anamorelin Hydrochloride, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients

NCT03867916
View directory record Official record
Conditions
Caregiver, Malignant Neoplasm, Physician, Stage I Colorectal Cancer AJCC v8, Stage I Liver Cancer, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Liver Cancer, Stage II Lung Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Liver Cancer, Stage III Lung Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Patient Navigation Program, Quality-of-Life Assessment, Survey Administration
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 28, 2026, 4:36 PM EDT
Active, not recruiting Phase 2 Interventional

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Interventions
RP1, nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

NCT02346955
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer
Interventions
CM-24 (MK-6018), Pembrolizumab (MK-3475)
Biological
Lead sponsor
Famewave Ltd.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

NCT00003726
View directory record Official record
Conditions
Lung Cancer
Interventions
lepirudin
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Priming Immunotherapy in Advanced Disease With Radiation

NCT03313804
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Immune checkpoint inhibitor, Radiation Therapy
Drug · Radiation
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

NCT02381314
View directory record Official record
Conditions
Melanoma, Non Small Cell Lung Cancer
Interventions
enoblituzumab plus ipilimumab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Miami Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional Results available

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

NCT02511184
View directory record Official record
Conditions
ALK-positive Advanced NSCLC
Interventions
Crizotinib, Pembrolizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 28, 2026, 4:36 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ABBV-706, Cisplatin, Budigalimab, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Gilbert, Arizona • Duarte, California • Irvine, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)

NCT00673738
View directory record Official record
Conditions
Lung Cancer
Interventions
Cetuximab, Conformal Thoracic Radiotherapy (CTRT)
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT03054038
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Afatinib, Necitumumab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Duarte, California • Stanford, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

NCT00769067
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Erlotinib, PF-00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
26
States / cities
Muscle Shoals, Alabama • Montebello, California • Bridgeport, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 28, 2026, 4:36 PM EDT
Completed No phase listed Observational

A Study of Personalized Neoantigen Cancer Vaccines

NCT03794128
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
Blood collection for research (next-generation sequencing [NGS]), Blood collection for research (HLA typing)
Procedure
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer

NCT00022711
View directory record Official record
Conditions
Lung Cancer
Interventions
temozolomide
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
17
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 28, 2026, 4:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

NCT05987644
View directory record Official record
Conditions
Lung Cancer, NSCLC, Brain Metastases
Interventions
Alectinib, Stereotactic Radiosurgery
Drug · Radiation
Lead sponsor
Joshua Palmer
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Interventions
XmAb®808, Keytruda® (pembrolizumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 28, 2026, 4:36 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers

NCT07553819
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Accelerometry, Aerobic Exercise, Biospecimen Collection, Educational Intervention, Electronic Health Record Review, Physical Performance Testing, Respiratory Muscle Training, Supportive Care, Survey Administration
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated Not applicable Interventional

Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL

NCT03220100
View directory record Official record
Conditions
Lung Cancer
Interventions
Stepped Palliative Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 28, 2026, 4:36 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer

NCT07216209
View directory record Official record
Conditions
Lung Cancer - Non Small Cell
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 28, 2026, 4:36 PM EDT